Drug Profile
Research programme: monoclonal antibody therapeutics - Emergent Biosolutions
Alternative Names: Viral haemorrhagic fever therapeutics- Emergent BiosolutionsLatest Information Update: 26 Dec 2022
Price :
$50
*
At a glance
- Originator Mapp Biopharmaceutical
- Developer Emergent BioSolutions
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Viral haemorrhagic fevers